| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7351401 | GE HEALTHCARE | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition |
Jan, 2023
(1 year, 3 months ago) | |
| US8236282 | GE HEALTHCARE | Benzothiazole derivative compounds, compositions and uses |
May, 2024
(23 days from now) | |
| US7270800 | GE HEALTHCARE | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
Sep, 2025
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8691185 | GE HEALTHCARE | Benzothiazole derivative compounds, compositions and uses |
Jan, 2023
(1 year, 3 months ago) | |
| US8916131 | GE HEALTHCARE | Radiopharmaceutical composition |
Sep, 2028
(4 years from now) | |
Vizamyl is owned by Ge Healthcare.
Vizamyl contains Flutemetamol F-18.
Vizamyl has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Vizamyl are:
- US8691185
- US7351401
Vizamyl was authorised for market use on 25 October, 2013.
Vizamyl is available in injectable;intravenous dosage forms.
Vizamyl can be used as diagnostic radioimaging.
Drug patent challenges can be filed against Vizamyl from 25 October, 2017.
The generics of Vizamyl are possible to be released after 16 September, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 25, 2018 |
Drugs and Companies using FLUTEMETAMOL F-18 ingredient
NCE-1 date: 25 October, 2017
Market Authorisation Date: 25 October, 2013
Treatment: Diagnostic radioimaging
Dosage: INJECTABLE;INTRAVENOUS
VIZAMYL family patents
